Piedmont Investment Advisors LLC Increases Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Piedmont Investment Advisors LLC increased its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 46,087 shares of the biopharmaceutical company’s stock after buying an additional 401 shares during the period. Piedmont Investment Advisors LLC’s holdings in Alexion Pharmaceuticals were worth $5,588,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ALXN. Russell Investments Group Ltd. acquired a new stake in Alexion Pharmaceuticals during the fourth quarter valued at $3,024,000. Dimensional Fund Advisors LP raised its stake in Alexion Pharmaceuticals by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 307,780 shares of the biopharmaceutical company’s stock valued at $37,660,000 after buying an additional 1,385 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Alexion Pharmaceuticals by 11.5% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,033 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 209 shares during the last quarter. Numeric Investors LLC purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at approximately $367,000. Finally, Elkhorn Investments LLC purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at approximately $756,000. Hedge funds and other institutional investors own 94.84% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 137.99 on Friday. The stock’s 50 day moving average is $123.43 and its 200-day moving average is $122.81. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.41. The company has a market cap of $30.99 billion, a P/E ratio of 65.74 and a beta of 1.39.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.48. The company had revenue of $912 million during the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. Alexion Pharmaceuticals’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.13 EPS. Analysts predict that Alexion Pharmaceuticals, Inc. will post $5.41 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/07/29/alexion-pharmaceuticals-inc-nasdaqalxn-shares-bought-by-piedmont-investment-advisors-llc-updated-updated-updated.html.

ALXN has been the topic of several analyst reports. Barclays PLC restated an “overweight” rating and issued a $155.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. UBS AG restated a “buy” rating and issued a $142.00 price target (up previously from $140.00) on shares of Alexion Pharmaceuticals in a research note on Monday, June 26th. Deutsche Bank AG dropped their price target on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Morgan Stanley restated an “overweight” rating and issued a $153.00 price target (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday. Finally, Raymond James Financial, Inc. reiterated a “strong-buy” rating and set a $176.00 price objective on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 9th. Six equities research analysts have rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $156.85.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson purchased 10,000 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, June 14th. The stock was acquired at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the transaction, the chief executive officer now owns 38,725 shares in the company, valued at approximately $4,519,982. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker purchased 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, June 14th. The stock was acquired at an average cost of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Insiders bought a total of 2,019,734 shares of company stock valued at $235,606,846 in the last quarter. 4.35% of the stock is currently owned by company insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply